SAGE Therapeutics, Inc. (US) (SAGE) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SAGE Therapeutics, Inc. is currently embroiled in a federal securities class action lawsuit and an SEC investigation, which pose significant business risks. These legal challenges could lead to substantial financial liabilities and distract management from strategic priorities. The outcome of these proceedings is uncertain, and potential adverse rulings could negatively affect the company’s financial health and reputation. The management’s focus on these issues might hinder the execution of essential business strategies crucial for growth.
Overall, Wall Street has a Hold consensus rating on SAGE stock based on 2 Buys, 1 Sell and 14 Holds.
To learn more about SAGE Therapeutics, Inc. (US)’s risk factors, click here.